Abbott (ABT) Stock Trades At A Cash Flow Discount But An Earnings Premium
Abbott Laboratories stock has fallen 16.4% over the past year, yet an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach points to meaningful upside compared with the current share price. With the broader valuation checks sitting in the middle of the range, investors are weighing whether that DCF upside is enough to offset recent share price weakness.
- The 1 year share price decline of 16.4% suggests the market has tempered its expectations for Abbott Laboratories despite the recent rebound in shorter term returns.
- Upcoming commercialization of Freenome's SimpleScreen CRC test in the U.S. and ongoing investment in the TriClip heart valve program can support long term cash flow, while intensifying competition in cancer screening and structural heart devices may limit how much value investors are willing to pay for that growth.
- Abbott Laboratories screens as a mixed opportunity on broader checks, with the stock appearing undervalued in 3 of 6 measures based on the value score.
The issue now is whether the current price already reflects these product opportunities, or if the 28.1% upside implied by the DCF intrinsic value still offers a margin of safety for Abbott Laboratories.
Find out why Abbott Laboratories' -16.4% return over the last year is lagging behind its peers.
Is Abbott Laboratories a Bargain on Cash Flow?
The Discounted Cash Flow model looks at the cash Abbott Laboratories can generate in the future and discounts it back to today. In this framework, Abbott is treated as a company with growing free cash flow rather than an early-stage turnaround story. Latest twelve month free cash flow sits at about $7.6b, with projections that assume this cash generation continues to expand over time.
On these assumptions, the DCF model points to an estimated intrinsic value of about $150 per share. That sits meaningfully above the current share price, which implies the stock trades at a 28.1% discount to the modelled value and therefore screens as undervalued. Because the FDA approval of Freenome's SimpleScreen CRC blood test gives Abbott Laboratories another potential cash flow source in cancer screening, the current discount suggests the market is still cautious on how much of that opportunity will translate into long-term cash generation.
Overall, the DCF workup suggests Abbott Laboratories stock appears undervalued relative to the cash flows currently expected from the business.
Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 28.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.
Is Abbott Laboratories Fairly Priced on Earnings?
The P/E ratio is a useful cross check for Abbott Laboratories because earnings remain a key reference point for many investors in large, profitable healthcare companies.
Abbott Laboratories currently trades on a P/E of 34.6x. That is above both the Medical Equipment industry average of 28.1x and the peer group average of 29.8x. On Simply Wall St’s fair P/E estimate of 36.8x, which adjusts for factors such as profitability, size and risk profile, the current multiple is slightly below what the model suggests investors might usually pay for Abbott’s earnings.
This points to a stock that is neither especially cheap nor stretched when viewed through earnings alone. The recent attention on Abbott’s roles in cancer screening and structural heart devices may help explain why the market is comfortable assigning a modest premium to the industry, while still keeping the multiple close to the modelled fair range.
Overall, Abbott Laboratories looks roughly fairly valued on its current P/E multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Abbott Laboratories Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Abbott Laboratories valuation checks leave off and explain the specific assumptions about growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today’s price. Each Narrative connects a fair value to a particular view of Abbott Laboratories' potential catalysts and risks so you can track which version of the story appears closer to reality over time via the Community page.
Add your voice to the Simply Wall St community with a Narrative on Abbott Laboratories' stock that sets out a clear, numbers based case and the key milestones you are watching.
You can build a view on whether developments such as the SimpleScreen CRC blood test and the TriClip heart valve program support the current share price or call for a different market reaction as new data and adoption trends emerge.
Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!
The Bottom Line
For Abbott Laboratories, the Discounted Cash Flow (DCF) work suggests the stock trades at a meaningful discount to its intrinsic value, while the current P/E points to pricing that looks about right compared with peers. The mixed result on the broader valuation checks means the stock does not screen as a clear bargain or a clear concern. The crux for investors is whether future cash flows from areas like cancer screening and structural heart devices are robust enough to close that DCF gap, or whether competitive and execution risks justify the current caution in the valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com